Life Sciences Tools and Services
Company Overview of Crown Bioscience, Inc.
Crown Bioscience, Inc., a preclinical CRO, provides drug discovery and development services to biotech and pharmaceutical partners focusing on oncology and metabolic disease therapeutic areas. The company’s proprietary HuPrime, HuKemia, HuBase, HuMark, HuTrial, and HuSignature platforms enable lead optimization and translational strategies to deliver clinical candidates. It offers oncology services, such as oncology databases, Ex vivo services, human surrogate trials, in vitro and in vivo services, preclinical formulations, translational research, and drug discovery services; and metabolic disease services, including in vivo and in vitro services, cardiovascular and metabolic disease (CVMD) ...
3375 Scott Boulevard
Santa Clara, CA 95054
Founded in 2006
Key Executives for Crown Bioscience, Inc.
Co-Founder, President and Chief Strategy Officer
President of International Institute of Biomedical Research (IIBR) and Senior Vice President of Cardiovascular & Metabolic Diseases (CVMD) Research
Compensation as of Fiscal Year 2016.
Crown Bioscience, Inc. Key Developments
Crown Bioscience Launches New Interactive Feature for XenoBase in Vitro Models
Sep 22 16
Crown Bioscience has published a further enriched version of its XenoBase, the online database collating cell line and cell line derived xenograft model data. The newly added module complements the existing database's powerful search options of publicly profiled data (gene expression, copy number and mutation) as well as proprietary histopathology, in vivo pharmacology, tumor growth and molecular pathology data for over 200 validated cell line derived xenograft models and for more than 1,000 tumor cell lines. With the new XenoBase feature, users will now be able to directly search and interact with dose response curves and IC50 data for over 290 cell lines, providing the ability to rapidly review and select the most appropriate model for their in vitro studies. Registered XenoBase users can already take advantage of the new feature, while new clients can simply send a request to register to start using the service from the company website.
Crown Bioscience Announces Executive Changes
Aug 30 16
Crown Bioscience announced that President, Dr. Jean Pierre Wery, has now moved into the role of Chief Executive Officer. In addition to Dr. Wery's recent nomination as CEO, Dr. Alex Wu, co-founder of CrownBio takes the role of President and Chief Strategy Officer, while Ms. Eva Ho has been appointed Chief Financial Officer. Ho brings years of experience in financial planning and analysis, having led the financial operations of well renowned global companies. Ho will take on Mr. Bing Zhu's previous role, who has now been appointed Chief Operating Officer.
Crown Bioscience Inc. Announces Board Appointments
Aug 25 16
Crown Bioscience Inc. has announced the appointment of Amar Thyagarajan, Ph.D., and Sandeep Sinha, Ph.D., to its team. Thyagarajan joins CrownBio as the associate director of product marketing and strategy. With extensive experience in bringing new products to market, he is responsible for the strategic and scientific marketing of CrownBio's cardiovascular and metabolic disease (CVMD) portfolio. Thyagarajan brings extensive scientific and senior product management experience with genetically engineered models used in neuroscience and CVMD drug discovery and safety and toxicology studies. Sinha is joining the team as scientific director and is responsible for providing direction to CrownBio's technical teams to build better partnerships with clients to execute successful CVMD programs. Prior to joining CrownBio, Sinha worked at Eli Lilly as a medical science liaison for diabetes and cardiovascular disease.
Similar Private Companies By Industry
Recent Private Companies Transactions